These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 35545195)

  • 1. First-generation oral antivirals against SARS-CoV-2.
    Sendi P; Razonable RR; Nelson SB; Soriano A; Gandhi RT
    Clin Microbiol Infect; 2022 Sep; 28(9):1230-1235. PubMed ID: 35545195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
    Atmar RL; Finch N
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
    Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
    Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
    Sutanto ST; Sinto R; Pasaribu A; Shakinah S
    Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
    Gentry CA; Nguyen P; Thind SK; Kurdgelashvili G; Williams RJ
    J Infect; 2023 Mar; 86(3):248-255. PubMed ID: 36702309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies.
    Mesfin YM; Blais JE; Kibret KT; Tegegne TK; Cowling BJ; Wu P
    J Antimicrob Chemother; 2024 Sep; 79(9):2119-2131. PubMed ID: 38817046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis.
    Jiang J; Li Y; Jiang Q; Jiang Y; Qin H; Li Y
    J Infect; 2024 Aug; 89(2):106190. PubMed ID: 38834107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
    Parums DV
    Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study.
    Drysdale M; Tibble H; Patel V; Gibbons DC; Lloyd EJ; Kerr W; Macdonald C; Birch HJ; Sheikh A
    BMC Infect Dis; 2024 Jul; 24(1):670. PubMed ID: 38965495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral antivirals for COVID-19 among patients with cancer.
    Guermazi D; Arvanitis P; Vieira K; Warner JL; Farmakiotis D
    Support Care Cancer; 2024 Jul; 32(8):496. PubMed ID: 38980433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study.
    Lai FTT; Wang B; Wei C; Chui CSL; Li X; Cheung CL; Wong ICK; Chan EWY; Wan EYF
    Age Ageing; 2024 Aug; 53(8):. PubMed ID: 39141078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.
    Lieber CM; Kang H-J; Sobolik EB; Sticher ZM; Ngo VL; Gewirtz AT; Kolykhalov AA; Natchus MG; Greninger AL; Suthar MS; Plemper RK
    J Virol; 2024 Sep; 98(9):e0090524. PubMed ID: 39207133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study.
    Wan EYF; Wong ZCT; Yan VKC; Chui CSL; Lai FTT; Li X; Wong ICK; Chan EWY
    Diabetes Obes Metab; 2024 Oct; 26(10):4653-4664. PubMed ID: 39109461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults.
    Levy ME; Burrows E; Chilunda V; Pawloski PA; Heaton PR; Grzymski J; Goldman JD; McEwen LM; Wyman D; Dei Rossi A; Dai H; Isaksson M; Washington NL; Basler T; Tsan K; Nguyen J; Ramirez J; Sandoval E; Lee W; Lu J; Luo S
    Clin Infect Dis; 2024 Jun; 78(6):1531-1535. PubMed ID: 38170452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.
    Salmanton-García J; Marchesi F; Koehler P; Weinbergerová B; Čolović N; Falces-Romero I; Buquicchio C; Farina F; van Praet J; Biernat MM; Itri F; Prezioso L; Tascini C; Vena A; Romano A; Delia M; Dávila-Valls J; Martín-Pérez S; Lavilla-Rubira E; Adžić-Vukičević T; García-Bordallo D; López-García A; Criscuolo M; Petzer V; Fracchiolla NS; Espigado I; Sili U; Meers S; Erben N; Cattaneo C; Tragiannidis A; Gavriilaki E; Schönlein M; Mitrovic M; Pantic N; Merelli M; Labrador J; Hernández-Rivas JÁ; Glenthøj A; Fouquet G; Del Principe MI; Dargenio M; Calbacho M; Besson C; Kohn M; Gräfe S; Hersby DS; Arellano E; Çolak GM; Wolf D; Marchetti M; Nordlander A; Blennow O; Cordoba R; Mišković B; Mladenović M; Bavastro M; Limongelli A; Rahimli L; Pagano L; Cornely OA
    Int J Antimicrob Agents; 2023 Oct; 62(4):106952. PubMed ID: 37582478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.
    Spiliopoulou V; Ntanasis-Stathopoulos I; Malandrakis P; Gavriatopoulou M; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Eleutherakis-Papaiakovou E; Kastritis E; Dimopoulos MA; Terpos E
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.